ANZCTR search results

The FNQHAT is a pragmatic randomised controlled trial which aims to reduce avoidable hospitalisations and Emergency Department visits for ‘frequent flyer’ adults with diabetes, cardiovascular disease, renal disease and chronic obstructive pulmonary disease. The primary objective is to improve primary health care-level chronic care processes (such as benchmarking, care planning and guideline concordance) and also patient outcomes (such as clinical indicator change, avoidable hospitalisations and ED visits and disease progression). FNQHAT is funded through the Queensland Department of Health’s Health Innovation Fund (HIF) as a joint project between the Cairns and Hinterland Hospital and Health Service (CHHHS) and James Cook University (JCU) Centre for Chronic Disease Prevention in Cairns. The CHHHS Sponsor is Dr Neil Beaton and the JCU lead is Professor Robyn McDermott. The study aims to recruit up to 530 “frequent flyers” over a 12-24-month period. People with chronic disease who have been identified as visiting one of the three participating hospitals in FNQ (Cairns Hospital, Innisfail Hospital and Mareeba Hospital) will be recruited. At least 25% of participants are expected to be Aboriginal or Torres Strait Islander and therefore the project will be undertaken in collaboration with the relevant Aboriginal Medical Services, WuChopperen in Cairns, Mamu in Innisfail and Mulungu in Mareeba. The study will compare usual best practice for managing chronic disease in the community (referral to GP) with close case management of clients in addition to usual best practice care. The study will also be trialling software which can connect to both the hospital and primary health care information systems. This will enable the use of a single patient record by the whole care team and will assist in communication between different health services, generating patient management plans and reporting on clinical care processes and measures. A Clinical Governance Group will also be established to oversee provision of care provided to participants and a Data Safety and Monitoring Group will monitor data quality and adverse events and to ensure participant safety throughout the study. Potential patients for the trial will be identified from EDIS and HBCIS data in participating hospitals according to the following eligibility criteria: (1) Had 8 or more presentations to the ED and/or hospitalisations in the previous 12 months for a potentially preventable hospitalisation (2) Aged 18-75 and reside within the area of a participating site. (3) Have at least one chronic condition identified (diabetes, cardiovascular disease, renal disease or chronic obstructive pulmonary disease).

This study aims to determine whether adding the drug, Tocilizumab, to standard transplant immunosuppression is safe and effective at preventing acute graft versus host disease (GVHD). You may be eligible to join this study if you are aged between 18 and 65 and are undertaking an HLA-mismatched allogeneic haematopoietic cell transplantation (HPCT). Trial details all participants inthis trial will receive a single dose of 8mg/kg Tocilizumab by a 60 minute intravenous infusion (administered via the vein). This will occur one day before your HPCT. Participants will be assessed for up to 2 years to determine the incidence of GVHD.

Delirium occurs commonly in hospitalised older patients and is frequently under-diagnosed and mistreated. There are two major shortfalls in Emergency Department (ED) care related to delirium: failure to diagnose and treat already established delirium, and failure to prevent the development of delirium. This study will test whether a screening process we have developed to identify delirium risk, coupled with the use of diagnostic and preventative measures in the ED and during hospital admission, will address these shortfalls.

To determine the feasibility and efficacy of 3 months of self-management support for increasing physical activity in people with mild disability after stroke

Steroids are commonly used medications used to treat for inflammatory conditions. They raise glucose levels. In this study, we will test in people with type 2 diabetes whether changing the timing of doses of oral steroids to twice a day administration, compared to the usual morning dosing, produces a more even pattern of glucose levels and less glucose fluctuation. The study will use continuous glucose monitoring to assess glucose patterns before, during and after three days of steroids.

The purpose of this study is to demonstrate that neurostimulation increases tear production and improves symptoms of dry eye disease over baseline measurements.

Surgical removal of the thyroid gland is a relatively safe procedure, but can be associated with a number of specific complications. The parathyroid glands are close to the thyroid gland and can be affected by the surgery. These glands help to maintain calcium levels in the blood and damage to these glands from the surgery can result in low blood calcium levels. Low calcium levels can result in tingling, numbness and muscle cramps. The condition is usually treated with Vitamin D and calcium supplements after it occurs and may prolong the length of stay in hospital. Vitamin D is a very important vitamin that helps to control bone and calium metabolism in the body. This study wants to see if by giving Vitamin D before the surgery low calcium levels can be prevented.

Patients with some diseases (e.g some cancers) or donors) may have stem cell mobilization treatments to increase numbers of stem cells released into the blood from bone marrow. These can then be harvested from the blood for the patient to use for replenishment after chemotherapy. Preliminary data in mice and humans support investigating ATL1102 as an agent for mobilising stem cells, in combination with G-CSF. The trial participation period will be approximately six weeks, which includes screening, treatment and post-dose study follow-up. There will be a total of five clinical trial visits per subject.

Currently, patients are required to attend outpatient clinics for face to face assessment of medical conditions by clinical staff prior to elective surgery. It is hypothesised that a computer-assisted smart questionnaire, delivered by phone, will provide information of sufficient quality to allow patients to be assessed by clinicians on the day of surgery, rather than at a separate preoperative hospital visit. A three phase approach to piloting this new process for preoperative assessment is proposed as follows: Phase 1: Phone screening in parallel with standard outpatients visits at LMHS and TQEH. Call centre data marked but not used for patient treatment. Phase 2: Prospective trial of a total of 1,000 patients at TQEH and the RAH. All patients will attend a streamlined outpatient clinic after phone pre-screening Phase 3: A further 1,000 patients at TQEH and the RAH will be screened by telephone and then triaged to either a streamlined outpatient review or bypass out patinet review and assessed by the anaesthetist on day of surgery. In all cases treating anaesthetists will be asked to mark the pre-assessements for errors or omissions.

There is an increasing body of evidence that the adoption of POC guided coagulation and haemostatic management algorithms in the severely injured trauma patient and in critical bleeding results in improved outcomes. We aim to critically evaluate our POC programme at the Gold Coast University Hospital (GCUH).